5 known cases. View patent page →
The accused products are the 0.75 mg, 1 mg, and 4 mg extended-release tacrolimus tablets sold under the brand name ENVARSUS XR.
This case alleges patent infringement due to the defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA, seeking to market generic tacrolimus extended-release tablets before the expiration of Veloxis's patents, including US11419823. Veloxis is seeking favorable judgment, an order preventing the defendants from manufacturing their ANDA products, damages, and litigation fees.
This case, filed on June 19, 2024, is currently at the 'Start Trial' stage in the District Court, D. Delaware.
This ANDA case, filed on July 3, 2024, in the U.S. District Court for the District of Delaware, is now closed.
This ongoing case involved a 'Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA)' filing on April 14, 2025, and continues with proposed protective orders and scheduling orders in August 2025.